We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multiviral Pathogen Detection System to Revolutionize Rapid Infectious Disease Diagnosis and Tracking

By LabMedica International staff writers
Posted on 22 Jun 2022
Print article
Image: Dragonfly is a cost-effective point-of-need portable diagnostic system for infectious diseases (Photo courtesy of ProtonDx)
Image: Dragonfly is a cost-effective point-of-need portable diagnostic system for infectious diseases (Photo courtesy of ProtonDx)

An innovative molecular testing technology platform designed to rapidly and simultaneously detect and differentiate multiple pathogens with high sensitivity and specificity is poised to help revolutionize rapid infectious disease diagnosis and tracking worldwide.

ProtonDx Ltd.’s (London, UK) Dragonfly is a portable, rapid diagnostic system that is able to identify multiple viral pathogens at the point of need. This revolutionary approach allows severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV) and human rhinovirus (HRV) to be detected in a single test. Using proprietary ultra-fast nucleic acid extraction, and isothermal colourimetric detection, the system achieves PCR equivalent sensitivity and specificity in less than 30 minutes from sample to result.

The Dragonfly diagnostic system incorporates the proprietary SmartLid sample preparation system to yield high purity DNA and RNA, enabling highly sensitive and accurate pathogen detection. The sample is added to a test panel, incubated, and the result can be captured and stored for traceability by the associated Dragonfly application. Dragonfly is a scalable platform with the flexibility to readily support detection of additional pathogens using the same core technology.

Dragonfly is uniquely suited for infectious disease testing in healthcare settings where portability and quick access to accurate results can support timely treatment decision-making, helping to minimize unnecessary antibiotic use. It is also suitable for use in care homes, the workplace, at sporting and entertainment events, and for travel where testing prior to close contact can avoid disruption and minimize risk to health and wellbeing. The system was successfully employed by Team GB at the 2022 Winter Olympic Games in Beijing, China. The Dragonfly system has received a CE-IVD Mark and complies with the European In-Vitro Diagnostic Devices (IVDD 98/79/EC) which means it is commercially available as an in vitro diagnostic tool in Europe.

“We are excited to be delivering an independent infectious disease identification and testing capability for use when confidence, portability, ease-of-use and immediacy are a real priority,” said Robert Enck, Chairman and President of ProtonDx. “With Dragonfly, we are pleased to offer a proven testing solution that delivers certainty, irrespective of location, in these testing times.”

“The Dragonfly system has been designed specifically to detect and differentiate multiple pathogens simultaneously with confidence,” added Dr. Jesus Rodriguez-Manzano, co-founder and CSO at ProtonDx. “From a simple respiratory swab with minimal handling, high quality nucleic acids are extracted and provide results equivalent to gold standard laboratory-based PCR, outside of the lab environment at the point-of-need. The Dragonfly system also validates that the sample has been taken and tested correctly to provide added confidence.”

Related Links:
ProtonDx Ltd.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.